Corporate Governance

Paul has served as a Director since September 2007. He is co-founder, President & CEO of PanOptica, Inc, a private venture-backed biopharmaceutical company that licenses and develops drugs for the treatment of important ophthalmic conditions, and has held such positions since March 2009. Prior to founding PanOptica, Paul was Executive Vice President and President of Eyetech Pharmaceuticals Inc. Previously, he was Chief Operating Officer of Eyetech, where he was responsible for the launch of Macugen, the first anti-VEGF treatment for neovascular age-related macular degeneration (wet-AMD) and was part of the executive team that led Eyetech’s initial public offering in 2004 through the Company’s acquisition by OSI Pharmaceuticals. Paul has held senior management positions at Pharmacia Corporation and began his career at the Upjohn Company in 1980. Paul earned a double BA in English and Biological Sciences from the University of Delaware.

Ken currently serves as Chief Financial Officer & Executive Vice President at Avid Technology, where he is responsible for driving strategic growth initiatives, capital allocation, and repositioning the company with the investment community. Previously, he served as Chief Financial Officer and interim Chief Executive Officer for Numerex, where he played a significant role in the company’s acquisition by Sierra Wireless and was Chief Financial Officer for Osmotica Pharmaceutical Inc. Ken has also had senior finance and investment banking roles with UBS Investment Bank and CIBC World Markets. He earned his MBA from Cornell University and his B.S. in finance from Boston College.

Dr. Hollander currently serves as Chief Research & Development Officer of Aerie Pharmaceuticals where he is responsible for overseeing clinical, preclinical and development groups, as well as medical and professional affairs. Previously he served as the Chief Medical Officer, Senior Vice President at Ora, Inc, an ophthalmic-specific contract research organization. Prior to this, he spent a decade at Allergan with increasing leadership roles, including Head of EyeCare for Global Medical Affairs, as well as VP and Therapeutic Area Head of Anterior Segment Clinical Development.

Erin was appointed as an independent Director for Kiora Pharmaceuticals in early 2022. She brings extensive knowledge and experience of the eyecare industry, and a broad clinical understanding of major ophthalmic diseases. During her career, she participated in the commercialization of XIIDRA®, OXERVATE®, LUCENTIS®, BEOVU®, DUREZOL®, and ZIRGAN®, among others.

In 2010, she founded Parsons Medical Communications where she currently serves as President. This leading agency provides scientific and strategic consulting to small and large companies in the ophthalmic space. Prior to PMC, she was a founding member of Sirion Therapeutics where she led the Medical Communications department. Erin is involved with various associations in the eyecare space including Ophthalmic World Leaders, Ophthalmic Innovation Summit and The Holland Foundation for Sight. Erin holds a BS in Biology from Wake Forest University.

Aron is currently Senior Vice President and Partner in the Asset Development & Partnering group at Ora, Inc. He is responsible for Ora’s strategic partnering activities, where he evaluates and performs diligence on new investment opportunities. Previously, Aron was responsible for establishing and leading clinical regulatory strategy and clinical operations across a number of anterior and posterior segment indications for Ora’s service business in ophthalmology and was responsible for Ora’s business development and international growth strategy. He earned his B.S. in biological chemistry from Bates College.

Praveen has served as a Director since June 2008. He is currently President & CEO of Invectys, Inc, an immuno-oncology company spun out of the world-renowned Pasteur Institute, Paris. Previously, he was Executive Vice President of Research & Development at Lexicon Pharmaceuticals. Until February 2016, Dr. Tyle was President, Chief Executive Officer and Member of the Board of Directors of Osmotica Pharmaceutical Corp. He led the merger of Osmotica with two other companies in 2016. He previously served as global Executive Vice President, Chief Scientific Officer and Managing Director of Osmotica Pharmaceutical Corp.’s Marietta, Georgia site. Prior to joining Osmotica, Dr. Tyle served as Executive Vice President and Chief Science Officer for the United States Pharmacopeia (USP). Prior to joining USP, Dr. Tyle served as Senior Vice President and Global Head of Business Development and Licensing at Novartis OTC, as well as Senior Vice President and Global Head of Research and Development. He also is an independent member of the board of Orient EuroPharma Co., Ltd. of Taiwan and a member of the advisory board of Pharmascience, Montreal, Canada. Dr. Tyle holds a doctorate in pharmaceutics and pharmaceutical chemistry from the Ohio State University and a Bachelor in Pharmacy (honors) from the Indian Institute of Technology, Banaras Hindu University in India.

Brian was a co-founder and Director of Bayon Therapeutics, Inc., and Okogen, Inc. Prior to founding Okogen, Brian worked at Sound Pharmaceuticals, Allergan and Shire, where he was responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments. Brian received his BS in Bioengineering from Cornell University and his PhD in Biomedical Engineering from UCLA.